A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.
The goal of this clinical research study is to learn if pembrolizumab and MK-3475 can help to control multiple myeloma when given in combination with standard of care treatments. The safety of this drug combination will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 10/27/2014
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: